首页 > 最新文献

Revista de Gastroenterologia de Mexico最新文献

英文 中文
Comentario sobre el «Primer consenso mexicano de la enfermedad de Crohn». El punto de vista del patólogo 关于克罗恩病的第一个墨西哥共识。病理学家的观点
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.10.005
J.A. Teco-Cortes
{"title":"Comentario sobre el «Primer consenso mexicano de la enfermedad de Crohn». El punto de vista del patólogo","authors":"J.A. Teco-Cortes","doi":"10.1016/j.rgmx.2024.10.005","DOIUrl":"10.1016/j.rgmx.2024.10.005","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Page 342"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experiencia en la vida real con el diagnóstico de malabsorción de ácidos biliares (MAAB) utilizando 7-alfa-C4 sérico y ácidos biliares en heces de 48 horas 使用7- alpha -C4血清和胆酸在粪便中48小时诊断胆酸吸收不良（MAAB）的实际经验
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.08.006
G. Mendoza-Domínguez , Z.M. Garrido-Santos , C. Lau , R. Balbuena , A.D. Santana-Vargas , M. Schmulson-Wasserman

Introduction

Bile acid malabsorption (BAM) is responsible for 30% of cases of diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea and 63.5% of cases of diarrhea following cholecystectomy. 75SeHCAT is the gold standard diagnostic method but is unavailable in Mexico. Alternatively, primary bile acid (PBA) and total bile acid (TBA) determination in 48 h stools and 7αC4 measurement have been proposed as screening tests.

Objective

Our aim was to evaluate the experience with PBAs and/or TBAs and to determine whether 7αC4 is a good screening biomarker for BAM in clinical practice.

Material and methods

An ambispective study of patients with chronic diarrhea was conducted. BAM was considered present with 7αC4 > 55 ng/mL (cost $420.00 USD), PBAs ≥ 9.8%, TBAs > 2,337 μmol/48 h, or TBAs > 1,000 μmol/48 h + PBAs > 4% (TBAs + PBAs) ($405.00 USD). However, those tests must be shipped to the US for their analysis (total cost $825.00 USD). Data were compared using the chi-square test and Student's t test, and Spearman's Rho correlations were calculated.

Results

We analyzed 48 patients with 7αC4 (age: 58.4 ± 16.9, women: 54.2%). BAM was confirmed by 7αC4 in 12.5%, by PBAs in 38.9%; by TBAs in 5.5%, and by TBAs + PBAs in 16.7%. We found elevated 7αC4 in patients with high or normal PBA/TBA levels (correlation with TBAs: 0.542, P = .020; PBAs: −0.127, P = .605; TBAs + PBAs: −0.200, P = .426). Lastly, BAM identified by 7αC4 was more frequent in patients with previous cholecystectomy (22.7%) vs. those without (3.8%).

Conclusions

Our study confirms that 7αC4 correlates well with TBAs and is a good biomarker for BAM screening because it can be elevated, despite normal PBA/TBA levels. Additionally, it represents a 49% cost savings in BAM investigation.
30%以腹泻为主的肠易激综合征（IBS-D）或功能性腹泻是由胆汁酸吸收不良（BAM）引起的，63.5%的胆囊切除术后腹泻是由胆汁酸吸收不良（BAM）引起的。sehcat是金标准诊断方法，但在墨西哥没有。另外，48 h粪便中原发性胆汁酸（PBA）和总胆汁酸（TBA）的测定和7αC4的测定也被提议作为筛选试验。我们的目的是评估PBAs和/或TBAs的经验，并确定7αC4在临床实践中是否是BAM的良好筛选生物标志物。材料与方法对慢性腹泻患者进行双透视研究。BAM被认为存在于7αC4 >；55 ng / mL(美元420.00美元),pba≥9.8%,稍后通知比;2,337 μmol/48 h，或TBAs >；1000 μmol/48 h + PBAs >；4% (tba + pba)（405.00美元）。但是，这些测试必须运往美国进行分析（总费用为825.00美元）。数据比较采用卡方检验和Student’st检验，计算Spearman’s Rho相关。结果分析48例7αC4患者（年龄：58.4±16.9，女性：54.2%）。7αC4和PBAs分别为12.5%和38.9%；TBAs和TBAs + PBAs的比例分别为5.5%和16.7%。我们发现PBA/TBA水平高或正常的患者中7αC4升高(与TBAs相关性：0.542,P = 0.020；PBAs:−0.127,P = 0.605；TBAs + PBAs:−0.200,P = .426)。最后，由7αC4识别的BAM在既往胆囊切除术患者中的发生率（22.7%）高于未行胆囊切除术患者（3.8%）。结论sour研究证实7αC4与TBA有良好的相关性，在PBA/TBA水平正常的情况下，7αC4可升高，是BAM筛选的良好生物标志物。此外，它还可以节省49%的BAM调查成本。
{"title":"Experiencia en la vida real con el diagnóstico de malabsorción de ácidos biliares (MAAB) utilizando 7-alfa-C4 sérico y ácidos biliares en heces de 48 horas","authors":"G. Mendoza-Domínguez ,&nbsp;Z.M. Garrido-Santos ,&nbsp;C. Lau ,&nbsp;R. Balbuena ,&nbsp;A.D. Santana-Vargas ,&nbsp;M. Schmulson-Wasserman","doi":"10.1016/j.rgmx.2024.08.006","DOIUrl":"10.1016/j.rgmx.2024.08.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Bile acid malabsorption (BAM) is responsible for 30% of cases of diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea and 63.5% of cases of diarrhea following cholecystectomy. <sup>75</sup>SeHCAT is the gold standard diagnostic method but is unavailable in Mexico. Alternatively, primary bile acid (PBA) and total bile acid (TBA) determination in 48<!--> <!-->h stools and 7αC4 measurement have been proposed as screening tests.</div></div><div><h3>Objective</h3><div>Our aim was to evaluate the experience with PBAs and/or TBAs and to determine whether 7αC4 is a good screening biomarker for BAM in clinical practice.</div></div><div><h3>Material and methods</h3><div>An ambispective study of patients with chronic diarrhea was conducted. BAM was considered present with 7αC4<!--> <!-->&gt;<!--> <!-->55<!--> <!-->ng/mL (cost $420.00<!--> <!-->USD), PBAs<!--> <!-->≥<!--> <!-->9.8%, TBAs<!--> <!-->&gt;<!--> <!-->2,337<!--> <!-->μmol/48<!--> <!-->h, or TBAs<!--> <!-->&gt;<!--> <!-->1,000<!--> <!-->μmol/48<!--> <!-->h +<!--> <!-->PBAs<!--> <!-->&gt;<!--> <!-->4% (TBAs<!--> <!-->+<!--> <!-->PBAs) ($405.00<!--> <!-->USD). However, those tests must be shipped to the US for their analysis (total cost $825.00 USD). Data were compared using the chi-square test and Student's t test, and Spearman's Rho correlations were calculated.</div></div><div><h3>Results</h3><div>We analyzed 48 patients with 7αC4 (age: 58.4<!--> <!-->± 16.9, women: 54.2%). BAM was confirmed by 7αC4 in 12.5%, by PBAs in 38.9%; by TBAs in 5.5%, and by TBAs<!--> <!-->+<!--> <!-->PBAs in 16.7%. We found elevated 7αC4 in patients with high or normal PBA/TBA levels (correlation with TBAs: 0.542, <em>P</em> <!-->=<!--> <!-->.020; PBAs: −0.127, <em>P</em> <!-->=<!--> <!-->.605; TBAs<!--> <!-->+<!--> <!-->PBAs: −0.200, <em>P</em> <!-->=<!--> <!-->.426). Lastly, BAM identified by 7αC4 was more frequent in patients with previous cholecystectomy (22.7%) vs. those without (3.8%).</div></div><div><h3>Conclusions</h3><div>Our study confirms that 7αC4 correlates well with TBAs and is a good biomarker for BAM screening because it can be elevated, despite normal PBA/TBA levels. Additionally, it represents a 49% cost savings in BAM investigation.</div></div>","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 169-175"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar? GLP-1类似物治疗的术前管理：停药还是个体化？
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.11.010
J. Crespo, P. Iruzubieta
{"title":"Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar?","authors":"J. Crespo,&nbsp;P. Iruzubieta","doi":"10.1016/j.rgmx.2024.11.010","DOIUrl":"10.1016/j.rgmx.2024.11.010","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 344-345"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impacto de la terapia de bioretroalimentación en el estreñimiento debido a la disinergia defecatoria 生物反馈疗法对缺乏症引起的便秘的影响
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.08.009
A. Fuentes-Montalvo, A.L. Ordóñez-Vázquez, J.S. Arenas-Martínez, E. Coss-Adame
{"title":"Impacto de la terapia de bioretroalimentación en el estreñimiento debido a la disinergia defecatoria","authors":"A. Fuentes-Montalvo,&nbsp;A.L. Ordóñez-Vázquez,&nbsp;J.S. Arenas-Martínez,&nbsp;E. Coss-Adame","doi":"10.1016/j.rgmx.2024.08.009","DOIUrl":"10.1016/j.rgmx.2024.08.009","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 311-313"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metástasis cutánea (letálide) umbilical como forma de presentación inicial de adenocarcinoma de sigma 脐带皮肤（致命）转移作为西格玛腺癌的一种初始形式
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.09.007
G. Renau, J. Domènech, A. Sánchez
{"title":"Metástasis cutánea (letálide) umbilical como forma de presentación inicial de adenocarcinoma de sigma","authors":"G. Renau,&nbsp;J. Domènech,&nbsp;A. Sánchez","doi":"10.1016/j.rgmx.2024.09.007","DOIUrl":"10.1016/j.rgmx.2024.09.007","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 314-315"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cambio de peso y modificaciones de estilo de vida implementados durante el confinamiento por la pandemia de COVID-19: correspondencia 2019冠状病毒病大流行封锁期间实施的体重变化和生活方式改变：通信
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.10.006
H. Daungsupawong , V. Wiwanitkit
{"title":"Cambio de peso y modificaciones de estilo de vida implementados durante el confinamiento por la pandemia de COVID-19: correspondencia","authors":"H. Daungsupawong ,&nbsp;V. Wiwanitkit","doi":"10.1016/j.rgmx.2024.10.006","DOIUrl":"10.1016/j.rgmx.2024.10.006","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 338-339"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Respuesta a Crespo et al., «Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar?» 对Crespo等人的回应，“GLP-1类似物治疗的术前管理：暂停还是个体化？”»
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.12.002
J.A. Velarde-Ruiz Velasco , J.R. Barrientos-Ávalos , E.C. Morel-Cerda
{"title":"Respuesta a Crespo et al., «Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar?»","authors":"J.A. Velarde-Ruiz Velasco ,&nbsp;J.R. Barrientos-Ávalos ,&nbsp;E.C. Morel-Cerda","doi":"10.1016/j.rgmx.2024.12.002","DOIUrl":"10.1016/j.rgmx.2024.12.002","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 345-346"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hamartoma de células de Schwann asociado a pólipo hiperplásico de colon: un hallazgo excepcional 与结肠增生性息痛相关的Schwann细胞蛋白酶瘤：一项杰出的发现
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.10.002
G. Castillo-López , S. González-Vázquez , T. Iscar-Galán , L. Alarcón-García , J.M. Riesco-López
{"title":"Hamartoma de células de Schwann asociado a pólipo hiperplásico de colon: un hallazgo excepcional","authors":"G. Castillo-López ,&nbsp;S. González-Vázquez ,&nbsp;T. Iscar-Galán ,&nbsp;L. Alarcón-García ,&nbsp;J.M. Riesco-López","doi":"10.1016/j.rgmx.2024.10.002","DOIUrl":"10.1016/j.rgmx.2024.10.002","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 316-318"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la dispepsia funcional. Revisión de expertos de la Asociación Mexicana de Gastroenterología 诊断和治疗功能性消化不良的良好临床实践建议。墨西哥胃肠病学协会专家审查
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.12.003
R.I. Carmona-Sánchez , G. Vázquez-Elizondo , M.C. Rodríguez-Leal , O. Gómez-Escudero , M.V. Bielsa-Fernández , E. Coss-Adame , K. García-Zermeño , P. Gómez-Castaños , M. Morales-Arámbula , E.C. Morel-Cerda , A. Noble-Lugo , J.M. Remes-Troche , S. Solórzano-Olmos , O.E. Trujillo-Benavides , M.A. Valdovinos-Díaz , L.R. Valdovinos-García

Introduction and aims

Functional dyspepsia (FD) is a highly prevalent condition characterized by upper gastrointestinal symptoms with no apparent organic cause. It is a complex and multifactorial disease that frequently overlaps with other disorders of gut-brain interaction. It is recurrent, has a variable therapeutic response, and affects patient quality of life. Our aim was to formulate good practice recommendations for the management of FD through a consensus review of the disease, updating and complementing the 2017 consensus on dyspepsia from the Asociación Mexicana de Gastroenterología (AMG).

Methods

Sixteen experts summoned by the AMG carried out a literature review (2017-2024) and formulated good clinical practice recommendations for the diagnosis and treatment of FD. They were discussed until reaching a consensus, and the most recent evidence on the theme was evaluated, utilizing the GRADE system.

Results

Twenty-three good clinical practice recommendations for the management of FD were developed that addressed the following aspects: 1) definition, pathophysiology, and epidemiology; 2) diagnosis; 3) nonpharmacologic treatment; 4) Helicobacter pylori eradication; 5) antisecretory and anti-acid therapy; and 6) prokinetics and neuromodulators.

Conclusions

The FD is one of the most frequent gastrointestinal conditions seen in daily practice. We present good clinical practice recommendations for the specific management of this disorder, taking into account the most recent advances that complement and update the consensus on dyspepsia published by the AMG in 2017.
简介和目的功能性消化不良（FD）是一种非常普遍的疾病，以上消化道症状为特征，无明显的器质性病因。它是一种复杂的多因素疾病，经常与其他肠脑相互作用疾病重叠。它是反复发作的，有不同的治疗反应，并影响患者的生活质量。我们的目标是通过对该疾病的共识审查制定FD管理的良好实践建议，更新和补充Asociación Mexicana de Gastroenterología (AMG) 2017年关于消化不良的共识。方法由AMG召集的16位专家进行文献综述（2017-2024），并制定FD诊断和治疗的良好临床实践建议。他们进行了讨论，直到达成共识，并利用GRADE系统评估了有关该主题的最新证据。结果针对FD的定义、病理生理学和流行病学，提出了23项临床管理建议；2)诊断;3)非药物治疗；4)幽门螺杆菌根除；5)抗分泌抗酸治疗；6)原动力学和神经调节剂。结论FD是临床上最常见的胃肠道疾病之一。考虑到AMG在2017年发布的关于消化不良共识的最新进展，我们提出了针对该疾病具体管理的良好临床实践建议。
{"title":"Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la dispepsia funcional. Revisión de expertos de la Asociación Mexicana de Gastroenterología","authors":"R.I. Carmona-Sánchez ,&nbsp;G. Vázquez-Elizondo ,&nbsp;M.C. Rodríguez-Leal ,&nbsp;O. Gómez-Escudero ,&nbsp;M.V. Bielsa-Fernández ,&nbsp;E. Coss-Adame ,&nbsp;K. García-Zermeño ,&nbsp;P. Gómez-Castaños ,&nbsp;M. Morales-Arámbula ,&nbsp;E.C. Morel-Cerda ,&nbsp;A. Noble-Lugo ,&nbsp;J.M. Remes-Troche ,&nbsp;S. Solórzano-Olmos ,&nbsp;O.E. Trujillo-Benavides ,&nbsp;M.A. Valdovinos-Díaz ,&nbsp;L.R. Valdovinos-García","doi":"10.1016/j.rgmx.2024.12.003","DOIUrl":"10.1016/j.rgmx.2024.12.003","url":null,"abstract":"<div><h3>Introduction and aims</h3><div>Functional dyspepsia (FD) is a highly prevalent condition characterized by upper gastrointestinal symptoms with no apparent organic cause. It is a complex and multifactorial disease that frequently overlaps with other disorders of gut-brain interaction. It is recurrent, has a variable therapeutic response, and affects patient quality of life. Our aim was to formulate good practice recommendations for the management of FD through a consensus review of the disease, updating and complementing the 2017 consensus on dyspepsia from the <em>Asociación Mexicana de Gastroenterología</em> (AMG).</div></div><div><h3>Methods</h3><div>Sixteen experts summoned by the AMG carried out a literature review (2017-2024) and formulated good clinical practice recommendations for the diagnosis and treatment of FD. They were discussed until reaching a consensus, and the most recent evidence on the theme was evaluated, utilizing the GRADE system.</div></div><div><h3>Results</h3><div>Twenty-three good clinical practice recommendations for the management of FD were developed that addressed the following aspects: 1) definition, pathophysiology, and epidemiology; 2) diagnosis; 3) nonpharmacologic treatment; 4) <em>Helicobacter pylori</em> eradication; 5) antisecretory and anti-acid therapy; and 6) prokinetics and neuromodulators.</div></div><div><h3>Conclusions</h3><div>The FD is one of the most frequent gastrointestinal conditions seen in daily practice. We present good clinical practice recommendations for the specific management of this disorder, taking into account the most recent advances that complement and update the consensus on dyspepsia published by the AMG in 2017.</div></div>","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 227-251"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Un tipo inusual de cáncer gástrico temprano con conducta agresiva: ¡no siempre es adenocarcinoma! 一种不寻常的早期胃癌，具有侵袭性：它并不总是腺癌！
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY
Revista de Gastroenterologia de Mexico
Pub Date : 2025-04-01 DOI: 10.1016/j.rgmx.2024.11.007
R. Ruiz , L. Marín-Calderón , H. Benites-Goñi , N. Fernández , M. Kapsoli
{"title":"Un tipo inusual de cáncer gástrico temprano con conducta agresiva: ¡no siempre es adenocarcinoma!","authors":"R. Ruiz ,&nbsp;L. Marín-Calderón ,&nbsp;H. Benites-Goñi ,&nbsp;N. Fernández ,&nbsp;M. Kapsoli","doi":"10.1016/j.rgmx.2024.11.007","DOIUrl":"10.1016/j.rgmx.2024.11.007","url":null,"abstract":"","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":"90 2","pages":"Pages 320-322"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Revista de Gastroenterologia de Mexico
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1